JP2024531338A5 - - Google Patents
Info
- Publication number
- JP2024531338A5 JP2024531338A5 JP2024509376A JP2024509376A JP2024531338A5 JP 2024531338 A5 JP2024531338 A5 JP 2024531338A5 JP 2024509376 A JP2024509376 A JP 2024509376A JP 2024509376 A JP2024509376 A JP 2024509376A JP 2024531338 A5 JP2024531338 A5 JP 2024531338A5
- Authority
- JP
- Japan
- Prior art keywords
- ifn
- inducible
- prodrug
- polypeptide
- cathepsin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163234284P | 2021-08-18 | 2021-08-18 | |
| US63/234,284 | 2021-08-18 | ||
| PCT/US2022/040564 WO2023023131A2 (en) | 2021-08-18 | 2022-08-17 | Activatable inteferon polypeptides and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024531338A JP2024531338A (ja) | 2024-08-29 |
| JP2024531338A5 true JP2024531338A5 (cg-RX-API-DMAC7.html) | 2025-08-25 |
Family
ID=83899708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024509376A Pending JP2024531338A (ja) | 2021-08-18 | 2022-08-17 | 活性化可能インターフェロンポリペプチド及びその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240216474A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4387987A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024531338A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118119634A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3228927A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202321284A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023023131A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230010251A (ko) | 2020-05-13 | 2023-01-18 | 보넘 테라퓨틱스, 인크. | 단백질 복합체의 조성물 및 그의 사용 방법 |
| CN116920114A (zh) * | 2022-04-08 | 2023-10-24 | 珠海市丽珠单抗生物技术有限公司 | 稳定的干扰素融合蛋白制剂及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006110728A2 (en) | 2005-04-12 | 2006-10-19 | The Uab Research Foundation | Immunogenic cmv tegument aggregates |
| US8399219B2 (en) * | 2009-02-23 | 2013-03-19 | Cytomx Therapeutics, Inc. | Protease activatable interferon alpha proprotein |
| JP2020528878A (ja) * | 2017-06-20 | 2020-10-01 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | がん治療用インターフェロンプロドラッグ |
| US20210130430A1 (en) * | 2018-05-14 | 2021-05-06 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| CN113286812B (zh) * | 2018-09-27 | 2025-05-30 | 西里欧发展公司 | 掩蔽型细胞因子多肽 |
| BR112022009110A2 (pt) * | 2019-11-14 | 2022-07-26 | Werewolf Therapeutics Inc | Polipeptídeos de citocina ativáveis e métodos de uso destes |
| WO2021158907A1 (en) * | 2020-02-06 | 2021-08-12 | Aetio Biotherapy, Inc. | Compositions and methods for treating viral infections |
-
2022
- 2022-08-17 EP EP22792938.7A patent/EP4387987A2/en active Pending
- 2022-08-17 JP JP2024509376A patent/JP2024531338A/ja active Pending
- 2022-08-17 CN CN202280070171.4A patent/CN118119634A/zh active Pending
- 2022-08-17 CA CA3228927A patent/CA3228927A1/en active Pending
- 2022-08-17 WO PCT/US2022/040564 patent/WO2023023131A2/en not_active Ceased
- 2022-08-18 TW TW111131193A patent/TW202321284A/zh unknown
-
2024
- 2024-02-13 US US18/440,841 patent/US20240216474A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023526428A5 (cg-RX-API-DMAC7.html) | ||
| JP2023503258A5 (cg-RX-API-DMAC7.html) | ||
| JP2021087429A5 (cg-RX-API-DMAC7.html) | ||
| US20210269530A1 (en) | Conditionally activated binding protein comprising a sterically occluded target binding domain | |
| JP2019513014A5 (cg-RX-API-DMAC7.html) | ||
| US20220267400A1 (en) | Il-2 cytokine prodrugs comprising a cleavable linker | |
| US7550143B2 (en) | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses | |
| WO2018097308A1 (ja) | リガンド結合活性が調整可能なリガンド結合分子 | |
| AU2021208553A1 (en) | Cytokine IL-2 prodrugs comprising a cleavable linker | |
| CN101374546A (zh) | 基于多价免疫球蛋白的生物活性装配体 | |
| JP2023552812A5 (cg-RX-API-DMAC7.html) | ||
| JP2018520642A5 (cg-RX-API-DMAC7.html) | ||
| US20240228586A1 (en) | Compositions and methods comprising protease-activated therapeutic agents | |
| JP2023540533A (ja) | ヒト血清アルブミンドメインを有する、制約され、条件付きで活性化された結合タンパク質構築物 | |
| IL298815A (en) | Bispecific compositions targeting HER-2 and methods for their preparation and use | |
| US20240216505A1 (en) | Inducible cytokine prodrug and pd-1/pd-l1 combination therapy | |
| JP2025511187A5 (cg-RX-API-DMAC7.html) | ||
| JP2024528660A (ja) | リンカーポリペプチド | |
| JP2024531338A (ja) | 活性化可能インターフェロンポリペプチド及びその使用方法 | |
| JP2025511190A5 (cg-RX-API-DMAC7.html) | ||
| EP4402157B1 (en) | Cleavable linkers | |
| WO2023143565A1 (en) | Anti-btla antibodies and uses thereof in treating cancer | |
| US20170121692A1 (en) | Methods for Generating Stably Linked Complexes Composed of Homodimers, Homotetramers or Dimers of Dimers and Uses | |
| RU2024125560A (ru) | Активируемые полипептиды интерлейкина 12 и способы их применения | |
| RU2023121219A (ru) | Активируемые полипептиды цитокинов и способы их применения |